{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015695","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.297299+00:00","generated_at":"2026-06-15T21:48:45.262528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avalo Q1 net loss narrows to $9.955M; cash $16.7M; AVTX-002 topline due Q2 2023","bullets":["Net loss $9.955M ($0.85/share) vs $22.051M ($2.35) in Q1 2022; revenue $475K down from $1.173M.","Cash and equivalents $16.687M at March 31, 2023, up $3.515M from Dec 31, 2022 due to $13.7M equity financing.","Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma completed enrollment (91 patients); topline data expected Q2 2023.","Operating expenses cut to $9.267M from $22.026M, driven by cost savings initiatives implemented in Q1 2022.","AVTX-008 lead molecule identified; IND submission planned for 2024. AVTX-803 LADDER trial timing under evaluation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015695","json":"https://secwatch.observer/filing/0001628280-23-015695.json","markdown":"https://secwatch.observer/filing/0001628280-23-015695.md","text":"https://secwatch.observer/filing/0001628280-23-015695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/0001628280-23-015695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/avtx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:48:45.262528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2b1bb3f4410def6eeb47db4a319819c14e54763","claim":"Avalo Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $475, net income $(9,955), EPS $(0.85).","evidence_excerpt":"Product revenue, net $ 475 $ 1,173 Total revenues, net 475 1,173 Operating expenses: Cost of product sales 551 720 Research and development 6,008 9,584 Selling, general and administrative 2,708 11,684 Amortization expense — 38 Total operating expenses 9,267 22,026 (8,792) (20,853) Other expense: Interest expense, net (949) (1,169) Change in fair value of derivative liability (180) — Other expense, net (26) (20) Total other expense, net (1,155) (1,189) Loss before taxes (9,947) (22,042) Income tax expense 8 9 Net loss and comprehensive loss $ (9,955) $ (22,051) Net loss per share of common stock, basic and diluted 1 $ (0.85) $ (2.35)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/0001628280-23-015695-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$475"},{"label":"Net income","value":"$(9,955)"},{"label":"EPS","value":"$(0.85)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}